Arcadia Biosciences
RKDA
Arcadia Biosciences (RKDA) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- −$0.85
- EPS estimate
- −$0.54
- EPS surprise
- −57.02%
- Revenue surprise
- −31.47%
- Revenue
- $1.3M
- Revenue estimate
- $1.9M
- Reported
- Nov 7, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 7, 2025 | −$0.54 | −$0.85 | −57.02% | $1.3M | SEC |
| Q2 2025 | Aug 14, 2025 | −$0.79 | −$3.26 | −312.66% | $1.5M | SEC |
| Q1 2025 | May 8, 2025 | −$0.98 | $1.90 | +293.88% | $1.2M | SEC |
| Q4 2024 | Mar 20, 2025 | −$0.89 | −$2.98 | −234.83% | $1.2M | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.81 | −$1.18 | −45.68% | $1.5M | SEC |
| Q2 2024 | Aug 13, 2024 | $1.55 | $0.78 | −49.68% | $1.3M | SEC |
| Q1 2024 | May 9, 2024 | −$2.22 | −$1.78 | +19.64% | $1.3M | SEC |
| Q4 2023 | Mar 28, 2024 | −$2.59 | −$2.10 | +18.76% | $1.2M | SEC |
| Q3 2023 | Nov 9, 2023 | −$2.93 | −$1.89 | +35.49% | $1.6M | SEC |
| Q2 2023 | Aug 10, 2023 | −$4.85 | $0.61 | +112.59% | $1.4M | SEC |
| Q1 2023 | May 11, 2023 | −$6.60 | −$7.80 | −18.11% | $1.5M | SEC |
| Q4 2022 | Mar 30, 2023 | −$6.80 | −$6.31 | +7.21% | $1.0M | SEC |
| Q3 2022 | Nov 10, 2022 | −$8.40 | −$4.80 | +42.86% | $1.9M | SEC |
| Q2 2022 | Aug 11, 2022 | −$11.60 | −$6.80 | +41.38% | $3.9M | SEC |
| Q1 2022 | May 12, 2022 | −$13.60 | −$8.59 | +36.83% | $3.2M | SEC |
| Q4 2021 | Mar 30, 2022 | −$12.00 | −$16.80 | −40.00% | $2.2M | SEC |
| Q3 2021 | Nov 15, 2021 | −$11.80 | $6.64 | +156.28% | $2.4M | SEC |
| Q2 2021 | Aug 16, 2021 | −$10.93 | −$13.83 | −26.54% | $1.4M | SEC |
| Q1 2021 | May 17, 2021 | −$13.73 | $4.40 | +132.04% | $828,000.00 | SEC |
| Q4 2020 | Mar 30, 2021 | −$16.40 | $36.00 | +319.51% | $7.1M | SEC |
Quarterly revenue
Frequently asked questions
When did Arcadia Biosciences (RKDA) last report earnings?
Arcadia Biosciences last reported on Nov 7, 2025, covering fiscal Q3 2025.
Did RKDA beat earnings estimates?
No. Arcadia Biosciences reported EPS of −$0.85 for Q3 2025 against a −$0.54 estimate — a 57.02% miss.
How much revenue did RKDA report last quarter?
Arcadia Biosciences reported $1.3M in revenue for Q3 2025, against a consensus estimate of $1.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.